Novartis hands rights to Tevimbra back to BeiGene

19 September 2023
beigenebig

Sino-American biotech BeiGene (HKEX: 06160) today announced that it has entered into an agreement with Novartis (NOVN: VX)  to regain worldwide rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), for which the Swiss pharma giant paid $650 million upfront in 2021.

Despite an initial dip, BeiGene’s shares closed up 1.4% at 144.82 renminbi following the news.

Just a couple on months ago, Novartis also pulled out of its option agreement with BeiGene for global rights to develop, manufacture and commercialize the investigational TIGIT inhibitor ociperlimab.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology